Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

News Conference News TCT 2022

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

Caitlin E. Cox

September 16, 2022

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

Caitlin E. Cox

October 14, 2020

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

Shelley Wood

September 27, 2019

News Conference News TCT 2015

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

October 11, 2015

Presentation TCT 2014

Controversies in Aortic Valve Disease: Challenging Clinical Scenarios (Asymptomatic AS, Low-Flow Low-Gradient AS, and Concomitant CAD)

Presenter: Blase A. Carabello, George D. Dangas

September 15, 2014

Presentation TCT 2014

TAVR On the Horizon: Emerging TAVR Platforms and Technologies

Presenter: Blase A. Carabello, George D. Dangas, Lutz Buellesfeld

September 15, 2014

Presentation TCT 2014

TAVR Update: FDA-Approved Valve Systems

Presenter: Blase A. Carabello, George D. Dangas, Alan C. Yeung

September 15, 2014

Presentation TCT 2014

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

Presenter: Blase A. Carabello, George D. Dangas, Patrick T. O'Gara

September 15, 2014

Presentation TCT 2014

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Presenter: Zoltan G. Turi, Jason Kovacic

September 14, 2014

Presentation TCT 2013

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Presenter: Anita Asgar

October 28, 2013

Presentation TCT 2012

Concurrent Coronary Artery and Valvular Heart Disease 1: Hybrid PCI with Surgical Valves

Presenter: Isaac George

October 23, 2012

Presentation TCT 2012

Concurrent Coronary Artery and Valvular Heart Disease 2: Hybrid PCI with Transcatheter Valves

Presenter: Jean-Michel Paradis

October 23, 2012

Presentation TCT 2012

The “Heart Team” Management Approach in Valvular Heart Disease: Components and Value Proposition - A Sustainable Model for the Future?

Presenter: A. Pieter Kappetein

October 22, 2012

Advertisement

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

TCT 2019 Day Two: Transcatheter Valves, New and Old

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

Controversies in Aortic Valve Disease: Challenging Clinical Scenarios (Asymptomatic AS, Low-Flow Low-Gradient AS, and Concomitant CAD)

TAVR On the Horizon: Emerging TAVR Platforms and Technologies

TAVR Update: FDA-Approved Valve Systems

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Concurrent Coronary Artery and Valvular Heart Disease 1: Hybrid PCI with Surgical Valves

Concurrent Coronary Artery and Valvular Heart Disease 2: Hybrid PCI with Transcatheter Valves

The “Heart Team” Management Approach in Valvular Heart Disease: Components and Value Proposition - A Sustainable Model for the Future?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content